Navigation Links
Antioxidant selenium offers no heart-disease protection

Selenium does not protect against cardiovascular disease, despite its documented antioxidant and chemopreventive properties, analysis of a randomized placebo-controlled clinical trial covering 13 years has shown. The selenium-CVD association was a secondary endpoint in the Nutritional Prevention of Cancer Trial, which was designed primarily to determine if selenium supplementation could prevent the recurrence of non-melanoma skin cancer.

Results of the trial, the only large randomized clinical trial to date to examine selenium supplementation alone in the prevention of CVD, appear in the April 15 issue of the American Journal of Epidemiology. Saverio Stranges, M.D., Ph.D., assistant professor of social and preventive medicine in the School of Public Health and Health Professions, University at Buffalo, is first author.

"Our results extend previous research based on smaller intervention trials focusing on cardiovascular risk factors," said Stranges. "Our findings are consistent with those from previous studies that have shown no beneficial effect of selenium supplementation in combination with other antioxidants on the primary prevention of cardiovascular disease."

Several antioxidants, vitamins C and E in particular, that were thought to play a role in preventing heart disease based on observational studies have turned out not to be protective in randomized clinical trials, and selenium now has joined this group.

The main findings of this report focus on the 1,004 participants in the study, conducted from 1983-96, who were free of cardiovascular disease when they were recruited. Participants came from seven dermatology clinics in low selenium areas of the eastern United States: Augusta and Macon, Ga.; Columbia, S.C.; Miami, Fla.; Wilson and Greenville, N. C.; and Newington, Conn.

Enrollees were assigned randomly to take a tablet containing 200 micrograms of selenium daily or a placebo. Information on sociodemographics, he alth habits, education and body mass index also was collected.

Participants provided blood samples at their respective clinics twice a year and reported any new illnesses or medications. Individuals were followed for an average of 7.6 years.

Results showed no association between selenium supplementation on any of the endpoints studied: coronary heart disease, stroke or deaths from cardiovascular disease, Stranges said. There also was no difference in the endpoints based on the level of selenium at baseline. In addition, the lack of significant association with CVD endpoints was confirmed even in the 246 participants who had CVD at baseline. (This data does not appear in the published manuscript.)

"These results must be interpreted cautiously," said Stranges, "because they result from exploratory analyses, although from the largest randomized clinical trial available that has selenium only as the intervention. However, this report adds important information to our knowledge on the role of selenium in cardiovascular-disease prevention, indicating no overall benefit of supplementation by selenium alone in prevention of cardiovascular disease."


'"/>

Source:University at Buffalo


Related biology news :

1. Antioxidant protects against lung damage in silicosis
2. Transgenic plants remove more selenium from polluted soil than wild plants, new tests show
3. New moth variety disarms plants guarded by selenium
4. Protein offers way to stop microscopic parasites in their tracks
5. Gene silencing technique offers new strategy for treating, curing disease
6. Mosaic mouse technique offers a powerful new tool to study diseases and genetics
7. Engineered skin offers clues to melanoma development
8. GM crop that holds on to its seeds offers higher yields
9. Novel enzyme offers new look at gene regulation
10. Technique offers new view of dynamic biological landscape
11. Microbiology text tells stories, offers online resources
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with ... today announced participation at the following conferences: ... Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at the ... York, NY . Agenus will participate in three ... Robert B. Stein , M.D., Ph.D., President, R&D ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... recently selected by the Connecticut Technology Council (CTC) as a 2017 Women of ... thirteenth annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
Breaking Biology Technology: